



30 June 2023 Pillar 3 report

UBS Europe SE

Table of contents

- 3 Introduction and basis for preparation
- 6 Key ratios
- 7 Own funds and eligible liabilities
- 12 Contacts

Introduction and basis for preparation

Scope of Pillar 3 disclosures

UBS Europe SE is a fully authorized credit institution registered at the commercial register in Frankfurt and supervised by the European Central Bank (ECB). This report provides the disclosure information for UBS Europe SE as at 30 June 2023.

The capital adequacy framework consists of three pillars each of which focuses on a different aspect of adequacy. Pillar 1 provides a framework for measuring minimum capital requirements for credit, market, operational and non-counterparty related risks faced by banks. Pillar 2 addresses the principles of the supervisory review process emphasizing the need for a qualitative approach to supervising banks. Pillar 3 aims to encourage market discipline by requiring banks to publish a range of disclosures, mainly on risk and capital.

This document is based upon the Regulation (EU) 2019/876 and Directive (EU) 2019/878 amending Regulation (EU) 575/2013, Regulation (EU) 648/2012 and Directive (EU) 2013/36, the associated delegated and implementing acts and the related Implementing Technical Standards (ITS), as implemented within the Federal Republic of Germany by the Bundesbank. Further, these disclosures have been prepared in accordance with the respective applicable European Banking Authority (EBA) guidelines.


For disclosures according to Section 26a German Banking Act ("Kreditwesengesetz" or "KWG") please see the respective section in our Annual Financial Statements as of 31 December 2022. For our firm's sustainability approach and activities please see UBS Group AG Sustainability Report 2022 at ubs.com/investors.

Regulatory consolidation

UBS Europe SE is part of the UBS Group AG consolidated group and a direct, wholly owned subsidiary of UBS AG. The scope of regulatory reporting for UBS Europe SE includes the Italian subsidiary UBS Fiduciaria. As the relevant limits according to Article 19 of the CRR are not exceeded, the German subsidiary UBS Private Equity Komplementär GmbH is not included in the regulatory scope of consolidation.

In accordance with the principle of materiality specified in Article 432 of the CRR, this report provides Pillar 3 disclosures for UBS Europe SE on the consolidated basis, including all relevant subsidiaries. In this report, "UBS Europe SE" refers to UBS Europe SE and its consolidated subsidiaries, unless stated otherwise.

Scope of regulatory consolidation



- Not Established in Germany
- 2 Foreign branches included Luxembourg, Sweden, Denmark, Italy, Spain, the Netherlands, France, Switzerland and Poland

rrance, switzeriano ano rola

Governance over Pillar 3 disclosures

The Management Board and senior management are responsible for establishing and maintaining an effective internal control structure over the disclosure of financial information, including Pillar 3 disclosures. In line with Article 431 of the CRR, UBS Europe SE has a board-approved Pillar 3 disclosure governance policy in place. This Pillar 3 report has been approved by the Chief Financial Officer of Europe SE, in line with this policy.

The UBS Europe SE Head of Regulatory Reporting formally attests that the disclosures provided in this document meet the requirements of the Part 8 of the CRR in accordance with formal UBS Europe SE policy and company's internal processes, systems and controls.

Format of Pillar 3 disclosures

The format of disclosures is based upon the respective applicable ITS. The comparative figures represent the latest disclosed period where applicable. Disclosures classified as non-material in accordance with Article 432 of the CRR and BaFin Circular 05/2015 in this report have been indicated accordingly in the respective sections. The table on the following page provides an overview of the Pillar 3 disclosures.

CRR Article	Pillar 3 Requirement	EU Table & Template Reference	Location of Pillar 3 disclosure in this report
437	Own Funds	EU CCA	Own funds and eligible liabilities
437a	Own funds and eligible liabilities	EU ILAC, EU TLAC2A EU CCA	Own funds and eligible liabilities
447	Key metrics	EU KM1	Key Metrics

Key ratios

The following is a summary of the key ratios of UBS Europe SE in accordance with Article 447 of the CRR.

EU KM1 - Key metrics

EUR m	30.06.23	31.12.22	30.06.22	31.12.21
Available own funds (amounts)	30.00.23	31.12.22	30.00.22	31.12.21
Common Equity Tier 1 (CET1) capital	2,438	2,441	2,427	2,764
Tier 1 capital	3,038	3,041	3,027	3,054
Total capital	3,038	3,041	3,027	3,054
Risk-weighted exposure amounts	44.440	40.726	44.442	42.220
Total risk exposure amount	11,118	10,726	11,412	12,328
Capital ratios (as a percentage of risk-weighted exposure amount)	24.020/	22.760/	24.250/	22.422/
Common Equity Tier 1 ratio (%)	21.93%	22.76%	21.26%	22.42%
Tier 1 ratio (%)	27.33%	28.35%	26.52%	24.77%
Total capital ratio (%)	27.33%	28.35%	26.52%	24.77%
Additional own funds requirements to address risks other than the risk of excessive leverage (as a percentage of risk- weighted exposure amount)				
Additional own funds requirements to address risks other than the risk of excessive leverage (%)	2.00%	2.25%	2.25%	2.50%
of which: to be made up of CET1 capital (percentage points)	1.13%	1.27%	1.27%	1.41%
of which: to be made up of Tier 1 capital (percentage points)	1.50%	1.69%	1.69%	1.88%
Total SREP own funds requirements (%)	10.00%	10.25%	10.25%	10.50%
Combined buffer and overall capital requirement (as a percentage of risk-weighted exposure amount)				
Capital conservation buffer (%)	2.50%	2.50%	2.50%	2.50%
Conservation buffer due to macro-prudential or systemic risk identified at the level of a Member State (%)				
Institution specific countercyclical capital buffer (%)	0.51%	0.28%	0.09%	0.11%
Systemic risk buffer (%)		0.2070	0.0370	0.7770
Combined buffer requirement (%)	3.01%	2.78%	2.59%	2.61%
	13.01%	13.03%	12.84%	13.11%
Overall capital requirements (%)				
CET1 available after meeting the total SREP own funds requirements(%)	16.30%	16.99%	15.50%	14.27%
Leverage ratio	40.254	41.010	47.264	46.660
Total exposure measure	49,351	41,818	47,364	46,660
Leverage ratio (%) ¹	6.16%	7.27%	6.39%	6.55%
Additional own funds requirements to address the risk of excessive leverage (as a percentage of total exposure measure)				
Additional own funds requirements to address the risk of excessive leverage (%)				
of which: to be made up of CET1 capital (percentage points)				
Total SREP leverage ratio requirements (%)	3.00%	3.00%	3.00%	3.00%
Leverage ratio buffer and overall leverage ratio requirement (as a percentage of total exposure measure)				
Leverage ratio buffer requirement (%)				
Overall leverage ratio requirement (%)	3.00%	3.00%	3.00%	3.00%
Liquidity Coverage Ratio				
Total high-quality liquid assets (HQLA) (Weighted value - average)	20,026	20,596	19,060	17,143
Cash outflows - Total weighted value	29,804	33,241	33,403	26,184
Cash inflows - Total weighted value	16,593	20,159	21,805	16,135
Total net cash outflows (adjusted value)	13,210	13,082	11,640	10,091
Liquidity coverage ratio (%)	152%	159%	166%	170%
Net Stable Funding Ratio	15270	1,55,70	10070	170/0
Total available stable funding	13,146	13,711	13,853	15,358
Total required stable funding	9,072	7,935	9,343	8,963
NSFR ratio (%)	145%		148%	171%
NOTR Idilo (%)	143%	173%	14070	1/1%

Referred to as 'Tier 1 leverage ratio' and 'Basel III leverage ratio' in UBS Group report as well as in UBS Group Pillar 3 report, respectively.

Own funds and eligible liabilities

The table below depicts the main features and terms and conditions of capital instruments issued by UBS Europe SE in accordance with Article 437 of the CRR.

EU CCA: Main features of regulatory own funds instruments and eligible liabilities instruments

	Common Equity Tier 1	Additional Tier 1	Additional Tier 1		Internal total loss-absorbing capacity (TLAC) eligible liabilities					
Issuer	UBS Europe SE	UBS Europe SE	UBS Europe SE		UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	UBS Europe SE	
Unique identifier (eg CUSIP, ISIN or Bloomberg identifier for private placement)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Public or private placement	Private	Private	Private	Private	Private	Private	Private	Private	Private	
Governing law(s) of the instrument	German	German	German	German	German	German	German	German	German	
Contractual recognition of write down and conversion powers of resolution authorities	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Regulatory treatment										
Transitional CRR rules	Common Equity Tier 1	Additional Tier 1	Additional Tier 1	Ineligible	Ineligible	Ineligible	Ineligible	Ineligible	Ineligible	
Post-transitional CRR rules	Common Equity Tier 1	Additional Tier 1	Additional Tier 1	Ineligible	Ineligible	Ineligible	Ineligible	Ineligible	Ineligible	
Eligible at solo/(sub-)consolidated/ solo & (sub-)consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	Solo and Consolidated	
Instrument type (types to be specified by each jurisdiction)	CET1 Instrument	Additional Tier 1	Additional Tier 1	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC	72b CRR - internal TLAC	
Amount recognised in regulatory capital (currency in million, as of most recent reporting date)	EUR 770 million	EUR 290 million	EUR 310 million		EUR 200 million	EUR 275 million	EUR 400 million	USD 300 million	EUR 400 million	
Nominal amount of instrument	EUR 446 million	EUR 290 million	EUR 310 million		EUR 200 million	EUR 275 million	EUR 400 million	USD 300 million	EUR 400 million	
Issue price	Various	1	1	1	1	1	1	1	1	
Redemption price	Par	Par	Par	Par	Par	Par	Par	Par	Par	
Accounting classification	Shareholders' equity	Shareholders' equity	Shareholders' equity	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost	Liability – amortised cost	
Original date of issuance	Various	11.06.2018	23.05.2022	27.02.2023	13.06.2022	14.05.2019	05.02.2021	03.11.2021	20.06.2023	
Perpetual or dated	Perpetual	Perpetual	Perpetual	Dated	Dated	Dated	Dated	Dated	Dated	
Original maturity date	No Maturity	No Maturity	No Maturity	27.02.2028	14.06.2027	14.05.2029	05.02.2031	03.11.2032	20.06.2025	
Issuer call subject to prior supervisory approval	N/A	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	

EU CCA: Main features of reg					le liabilitie	s instrume	nts (contin	ued)	
	Common Equity Tier 1		Additional Tier 1		Internal total I	oss-absorbing ca	apacity (TLAC) el	igible liabilities	
	, ,			1 year before contractual maturity, the	1 year before contractual maturity, the	contractual	contractual	contractual	1 year before contractual maturity, the
				Borrower, in	Borrower, in	Borrower, in	Borrower, in	Borrower, in	Borrower, in
				its sole discretion, has	its sole discretion, has	its sole discretion, has	its sole discretion, has	its sole discretion, has	its sole discretion, has
				the right to	the right to	the right to	the right to	the right to	the right to
				repay the outstanding	repay the outstanding	repay the outstanding	repay the outstanding	repay the outstanding	repay the outstanding
				principal	principal	principal	principal	principal	principal
				Loan+ any	amount of the Loan+ any	amount of the Loan+ any	Loan+ any	amount of the Loan+ any	Loan+ any
				accrued and	accrued and	accrued and	accrued and	accrued and	accrued and
				unpaid interest	unpaid interest	unpaid interest	unpaid interest	unpaid interest	unpaid interest
				thereon,	thereon,	thereon,	thereon,	thereon,	thereon,
				provided that the competent			provided that the competent		
				authority has	authority has	authority has	authority has	authority has	authority has
				approved such early	approved such early	approved such early	approved such early		approved such early
				repayment of	repayment of	repayment of	repayment of	repayment of	repayment of
		12.12.2023, or earlier upon	23.05.2027, or earlier upon	the Loan (if such approval	the Loan (if such approval		the Loan (if such approval		the Loan (if such approval
		occurrence of	occurrence of	is then	is then	is then	is then	is then	is then
		tax or regulatory		required under applicable law				required under applicable law	
Optional call date, contingent call dates and		event at par	event at par	and	and	and	and	and	and
redemption amount	N/A N/A			regulations)	regulations)	regulations)	regulations)	regulations)	regulations)
Subsequent call dates, if applicable Coupons I dividends	N/A	IN/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Fixed or floating dividend/coupon	Floating	Floating	Floating	Floating	Floating	Floating	Floating	Floating	Floating
		EURIBOR	×	3-month	3-month	3-month	3-month		3-month
Coupon rate and any related index	N/A	floored to zero + 466bps	EURIBOR +	EURIBOR floored to zero + 127bps	EURIBOR + 128bps	EURIBOR floored to zero + 103bps	EURIBOR floored to zero + 74bps	SOFR + 134bps	EURIBOR floored to zero + 198bps
Existence of a dividend stopper	No	No	No	No	No	No	No	No	No
Fully discretionary, partially discretionary or mandatory (in terms of timing)	Fully discretionary			Mandatory	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory
Fully discretionary, partially discretionary or mandatory (in terms of amount)	Fully discretionary			Mandatory	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory
Existence of step up or other incentive to redeem	No	No	No	No	No	No	No		No
Noncumulative or cumulative	Non- cumulative		Non- cumulative	Non cumulative	Non cumulative	Non cumulative	Non cumulative	Non cumulative	Non cumulative
Convertible or non-convertible	Non- convertible	Non- convertible	Non- convertible	Convertible	Convertible	Convertible	Convertible	Convertible	Convertible
If convertible, conversion trigger(s)	N/A	N/A	N/A	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority	Instruction of resolution authority	resolution	Instruction of resolution authority
If convertible, fully or partially	N/A	N/A	N/A	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially
If convertible, conversion rate	N/A	N/A	N/A	At discretion of resolution	At discretion of resolution	At discretion of resolution	At discretion of resolution	At discretion of resolution	At discretion of resolution
If convertible mandates as a stimul				authority Mandatory after	authority Mandatory after	authority Mandatory after	authority Mandatory after	authority Mandatory after	authority Mandatory after
If convertible, mandatory or optional conversion	N/A	N/A	N/A						instruction of resolution authority
If convertible, specify instrument type convertible into	N/A	N/A	N/A	CET1	CET1	CET1	CET1	CET1	CET1

EU CCA: Main features of regulatory own funds instruments and eligible liabilities instruments (continued)

LO CCA. Main reactives of reg			Additional Tier			oss-absorbing ca	•		
If convertible, specify issuer of instrument it converts into	N/A	N/A	N/A	UBS Europe SE					
Write-down features	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
If write-down, write-down trigger(s)	N/A	CET1 ratio falls below 5.125%	CET1 ratio falls below 5.125%	Instruction of resolution authority					
If write-down, full or partial	N/A	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially	Fully or Partially
If write-down, permanent or temporary	N/A	Temporary	Temporary	Permanent	Permanent	Permanent	Permanent	Permanent	Permanent
If temporary write-down, description of write-up mechanism	N/A	Contractual conversion rate of annual balance sheet profit		N/A	N/A	N/A	N/A	N/A	N/A
Type of subordination (only for eligible liabilities)	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory	Statutory
Ranking of the instrument in normal insolvency proceedings	1	2	2	5	5	5	5	5	5
Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument)	AT1	Shareholder loans	Shareholder loans	Senior non- preferred					
Non-compliant transitioned features	No	No	No	No	No	No	No	No	No
If yes, specify non-compliant features	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Link to the full term and conditions of the instrument (signposting)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

The following table provides an overview of key metrics and the internal loss-absorbing capacity in accordance with Article 437a of the CRR.

EU iLAC - Internal loss absorbing capacity: internal TLAC and, where applicable, requirement for own funds and eligible liabilities for non-EU G-SIIs

	30.06	.23	31.03	.23
EUR m	Non-EU G-SII Requirement for own funds and eligible liabilities (internal TLAC)	Qualitative information	Non-EU G-SII Requirement for own funds and eligible liabilities (internal TLAC)	Qualitative information
Applicable requirement and level of application	((
Is the entity subject to a Non-EU G-SII Requirement for own funds and eligible liabilities? (Y/N)		Υ		Υ
If EU 1 is answered by 'Yes', is the requirement applicable on a consolidated or individual basis? (C/I)		С		С
Is the entity subject to an internal MREL requirement? (Y/N)		Υ		Υ
If EU 2a is answered by 'Yes', is the requirement applicable on a consolidated or individual basis? (C/I)		С		С
Own funds and eligible liabilities				
Common Equity Tier 1 capital (CET1)	2,438		2,435	
Eligible Additional Tier 1 instruments	600		600	
Eligible Tier 2 instruments				
Eligible own funds	3,038		3,035	
Eligible liabilities	2,525		2,127	
of which permitted guarantees				
(Adjustments)				
Own funds and eligible liabilities items after adjustments	5,563		5,161	
Total risk exposure amount and total exposure measure				
Total risk exposure amount	11,118		10,561	
Total exposure measure	49,351		47,909	
Ratio of own funds and eligible liabilities				
Own funds and eligible liabilities (as a percentage of TREA)	50.04%		48.87%	
of which permitted guarantees				
Own funds and eligible liabilities (as a percentage of leverage exposure)	11.27%		10.77%	
of which permitted guarantees				
CET1 (as a percentage of TREA) available after meeting the entity's requirements	16.30%		17.43%	
Institution-specific combined buffer requirement	3.01%		2.88%	
Requirements				
Requirement expressed as a percentage of the total risk exposure amount	16.20%		16.20%	
of which may be met with guarantees				
Internal TLAC expressed as percentage of the total exposure measure	6.08%		6.08%	
of which may be met with guarantees				
Memorandum items				
Total amount of excluded liabilities referred to in Article 72a(2) CRR	30,689		31,268	

The following table depicts creditor ranking of instruments in accordance with Article 437a of the CRR.

EU TLAC2a: Creditor ranking - Entity that is not a resolution entity

30.06.22			Ins	solvency ranking					
	1	2	5	11					
	(most junior)								
	Resoluti-	Resoluti-	Resoluti-		_				
EUR m	on entity	on entity	on entity	Other	Tota				
Empty set in the EU									
Description of insolvency rank	Common equity Tier 1 instruments	Additional Tier 1 instruments	Claims for repayment of shareholder loans and accrued interest thereon	Non-preferred creditor claims arising from non- subordinated, unsecured non-structured debt instruments which (i) are issued before 21 July 2018 and are neither deposits within the positions of no. 13 and 14 nor money market instruments (ii) are issued from 21 July 2018 onwards, have an original contractual maturity of at least one year, do not qualify as deposits within the position of no. 13 and 14 and the contractual documentation and, where applicable, the prospectus explicitly refer to the lower ranking					
Liabilities and own funds including derivative liabilities	2,437	600	2,537	20	5,594				
of which excluded liabilities			12	5	17				
Liabilities and own funds less excluded liabilities	2,437	600	2,525	15	5,577				
Subset of liabilities and own funds less excluded liabilities that are own funds and eligible liabilities for the purpose of internal TLAC	2,437	600	2,525		5,562				
of which residual maturity ≥ 1 year < 2 years			400		400				
of which residual maturity ≥ 2 year < 5 years			1,175		1,175				
of which residual maturity ≥ 5 years < 10 years			950		950				
of which residual maturity ≥ 10 years, but excluding perpetual securities									
of which perpetual securities	2,437	600			3,037				
31.12.22	Insolvency ranking								
	1	2	5	11					
	(most junior)								
	Resoluti-	Resoluti-	Resoluti-						
EUR m	on entity	on entity	on entity	Other	Total				
Empty set in the EU									
Description of insolvency rank	Common equity Tier 1 instruments	Additional Tier 1 instruments	Claims for repayment of shareholder loans and accrued interest thereon	Non-preferred creditor claims arising from non- subordinated, unsecured non-structured debt instruments which (i) are issued before 21 July 2018 and are neither deposits within the positions of no. 13 and 14 nor money market instruments (ii) are issued from 21 July 2018 onwards, have an original contractual maturity of at least one year, do not qualify as deposits within the position of no. 13 and 14 and the contractual documentation and, where applicable, the prospectus explicitly refer to the lower ranking					
Liabilities and own funds including derivative liabilities	2,431	600	2,138	24	5,193				
of which excluded liabilities			8	9	17				
Liabilities and own funds less excluded liabilities	2,431	600	2,130	15	5,176				
Subset of liabilities and own funds less excluded liabilities that are own funds and eligible liabilities for the purpose of internal TLAC	2,431	600	2,130		5,161				
of which residual maturity ≥ 1 year < 2 years			975		975				
of which residual maturity ≥ 2 year < 5 years			200		200				
of which residual maturity ≥ 5 years < 10 years			955		955				
of which residual maturity ≥ 10 years, but excluding perpetual securities									

Contacts

Should you have any queries please contact the UBS Investor Relations team:

UBS Group AG Investor Relations P.O. Box CH-8098 Zurich Switzerland

Tel: +41-44-234 4100

Email: sh-investorrelations@ubs.com

ubs.com/investors

UBS Europe SE is a Societas Europaea registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Frankfurt am Main under HRB 107046. Registered business address: Bockenheimer Landstraße 2-4, OpernTurm, 60306 Frankfurt am Main. The Chairman of Supervisory Board of UBS Europe SE is Prof. Dr. Reto Francioni. The Management Board of UBS Europe SE is composed of Tobias Vogel (Chair), Heinrich Baer, Dr. Denise Bauer-Weiler, Pierre Chavenon, Georgia Paphiti.

UBS Europe SE is a subsidiary of UBS Group AG.

This document may contain statements that constitute "forward looking statements" including but not limited to statements relating to the anticipated effect of transactions described herein and other risks specific to UBS's business, strategic initiatives, future business development and economic performance. While these forward-looking statements represent UBS's judgements and expectations concerning the development of its business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from UBS's expectations.

This document is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to. It should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this material are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this material.

In this disclaimer UBS means UBS Group AG, UBS AG and UBS Europe SE.

The information contained within this document has not been audited by the external auditors of UBS Europe SE.

Numbers presented throughout this report may not add up precisely to the totals provided in the tables and text due to rounding.

ubs.com

